Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Uterine Cervical Neoplasms 2Uterine Cervical Dysplasia 2Vulvar Neoplasms 1Vaginal Neoplasms 1Precancerous Conditions 1Papillomavirus Infections 1Multiple Myeloma 1Leukemia, Plasma Cell 1Esophageal Neoplasms 1Barrett Esophagus 1Atypical Squamous Cells of the Cervix 1Adenocarcinoma Of Esophagus 1

Interventions

fludarabine phosphate 9fludarabine 8Whole-Body Irradiation 7Peripheral Blood Stem Cell Transplantation 7Melphalan 7Cyclophosphamide 7Mycophenolic Acid 6Lenalidomide 6Dexamethasone 6Tacrolimus 5Bortezomib 4Sirolimus 3ixazomib 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Stem Cell Transplantation 2Etoposide 2Cytarabine 2Cyclosporine 2Carmustine 2Calcium Dobesilate 2Antilymphocyte Serum 2Allopurinol 2talquetamab 1sargramostim 1pomalidomide 1montanide ISA 51 1merphos 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Plasma Cell × High-Throughput Screening Assays × Clear all
NCT03389347 2026-05-08

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

University of Washington

Phase NA Active not recruiting
40 enrolled 7 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡